Welcome to LookChem.com Sign In|Join Free

CAS

  • or

80040-79-5

Post Buying Request

80040-79-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

80040-79-5 Usage

Chemical Properties

White to yellowish crystalline powder

Uses

Different sources of media describe the Uses of 80040-79-5 differently. You can refer to the following data:
1. An important building block for solution- and solid-phase synthesis of oligosaccharides.
2. Tri-O-benzyl-D-glucal functions as a substance in the stereoselective synthesis of sphinganine and unnatural safingol acting as antineoplastic and antipsoriatic agent for cancer treatment, and affected skin patches.

Check Digit Verification of cas no

The CAS Registry Mumber 80040-79-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,0,0,4 and 0 respectively; the second part has 2 digits, 7 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 80040-79:
(7*8)+(6*0)+(5*0)+(4*4)+(3*0)+(2*7)+(1*9)=95
95 % 10 = 5
So 80040-79-5 is a valid CAS Registry Number.
InChI:InChI=1/C27H28O4/c1-4-10-22(11-5-1)18-28-21-26-27(31-20-24-14-8-3-9-15-24)25(16-17-29-26)30-19-23-12-6-2-7-13-23/h1-17,25-27H,18-21H2/t25-,26-,27-/m1/s1

80040-79-5 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Aldrich

  • (474797)  Tri-O-benzyl-D-galactal  98%

  • 80040-79-5

  • 474797-1G

  • 1,615.77CNY

  • Detail

80040-79-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name (2R,3R,4R)-3,4-bis(phenylmethoxy)-2-(phenylmethoxymethyl)-3,4-dihydro-2H-pyran

1.2 Other means of identification

Product number -
Other names 2,4,6-tri-O-benzyl-D-galalactal

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:80040-79-5 SDS

80040-79-5Relevant articles and documents

Iterative Synthesis of 2-Deoxyoligosaccharides Enabled by Stereoselective Visible-Light-Promoted Glycosylation

Guo, Zhen-Yan,Liu, Kai-Meng,Liu, Meng,Liu, Miao,Qin, Xian-Jin,Wang, Peng-Yu,Xiong, De-Cai,Xue, Wan-Ying,Ye, Xin-Shan

, (2022/02/21)

The photoinitiated intramolecular hydroetherification of alkenols has been used to form C?O bonds, but the intermolecular hydroetherification of alkenes with alcohols remains an unsolved challenge. We herein report the visible-light-promoted 2-deoxyglycosylation of alcohols with glycals. The glycosylation reaction was completed within 2 min in a high quantum yield (?=28.6). This method was suitable for a wide array of substrates and displayed good reaction yields and excellent stereoselectivity. The value of this protocol was further demonstrated by the iterative synthesis of 2-deoxyglycans with α-2-deoxyglycosidic linkages up to a 20-mer in length and digoxin with β-2-deoxyglycosidic linkages. Mechanistic studies indicated that this reaction involved a glycosyl radical cation intermediate and a photoinitiated chain process.

TARGETED BIFUNCTIONAL DEGRADERS

-

Page/Page column 34; 157; 169; 170, (2021/04/17)

The present invention provides, in one aspect, bifunctional compounds that can be used to promote or enhance degradation of certain circulating proteins. In another aspect, the present invention provides bifunctional compounds that can be used to promote or enhance degradation of certain autoantibodies. In certain embodiments, treatment or management of a disease and/or disorder requires degradation, removal, or reduction in concentration of the circulating protein or the autoantibody in the subject. Thus, in certain embodiments, administration of a compound of the invention to the subject removes or reduces the circulation concentration of the circulating protein or the autoantibody, thus treating, ameliorating, or preventing the disease and/or disorder. In certain embodiments, the circulating protein is TNF.

Ir(I)-Catalyzed C?H Glycosylation for Synthesis of 2-Indolyl-C-Deoxyglycosides

Yu, Changyue,Liu, Yichu,Xie, Xiong,Hu, Shulei,Zhang, Shurui,Zeng, Mingjie,Zhang, Dan,Wang, Jiang,Liu, Hong

supporting information, p. 4926 - 4931 (2021/09/09)

The construction of 2-deoxy-C-glycosides has gradually become a hotspot of carbohydrate chemistry in recent years. In this work, we present an efficient, regioselective, stereoselective and widely applicable strategy for the synthesis of 2-indolyl-C-deoxyglycosides via Ir(I)-catalyzed, pyridine-group-directed C?H functionalization. This method exhibits high tolerance for the functional groups of indoles and the protecting groups of carbohydrates. Moreover, this protocol has good stereoselectivity and mainly produces β-configuration products. Gram-scale synthesis and several practical transformations were conducted for further applications. Meantime, we also explored the mechanism of this method and proposed a catalytic cycle. (Figure presented.).

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 80040-79-5